121 results about "Neural cell" patented technology

The present disclosure provides materials and methods for delivery of a transgene to target cells. The regulatory elements, transgenes, and expression vectors are useful in, e.g., expressing a transgene in CNS cells that results in an improvement in at least one symptom related to a neurological disease or disorder, including epilepsy disorders, such as refractory epilepsy.

The present invention is directed to genetic manipulation of neural cells in the gyrencephalic fetal brain for developing treatment strategies for various neurodevelopmental disorders.

Described herein are techniques for identifying regions of substantia nigra reticulata (SNR) and regions of substantia nigra compact dorsal (SNCD) in histology images and quantifying a number of dopaminergic neural cells within the images. In some embodiments, an image of a section of a brain may be input into a first machine learning model to obtain a first segmentation map comprising pixel-wise labels indicative of whether a corresponding pixel in the image depicts a region of SNR or SNCD. In some embodiments, the image (and, optionally, the first segmentation map) may also be input to a second machine learning model trained to generate a second segmentation map comprising pixel-wise labels indicating whether a corresponding pixel of the image depicts a dopaminergic neural cell or neural background tissue. The number of cells within the image may be determined based on the second segmentation map.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

Disclosed herein are methods of treating ALS in a subject by administering to the subject a therapeutically effective amount of a composition comprising, for example, EV derived from nerve cells, such as neural progenitor cells. The EVs may be administered distally or peripherally to the CNS such that these EVs cross the blood-brain barrier and exert their therapeutic function in the CNS. The methods may reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and / or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in an ALS subject as compared to a control ALS subject. Also provided are methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EV.

The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3):(1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and / or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state,(2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

The invention relates to the technical field of nerve cell marking and regulation and control, in particular to a nerve cell living body selective protein modification probe capable of penetrating a blood brain barrier and application of the nerve cell living body selective protein modification probe. The protein body part specifically targets a living glutamic acid energetic neuron cell membrane, the protein body part and / or a modified part thereof can regulate and control the function of the glutamic acid energetic neuron, and a coding sequence of the protein body part comprises a sequence as shown in SEQ ID NO: 1 or a sequence having at least 85% identity with the SEQ ID NO: 1. The protein modified probe provided by the invention provides a new feasible thought for developing in-vivo nerve cell selective markers and regulation tools which are non-gene transfection of blood brain barrier penetration, are high in biological safety, are more stable and are easy to obtain and have nerve cell specific type selectivity.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The application belongs to the technical field of biological medical materials, and discloses a polydopamine modified modified nano-graphyne and a preparation method and application thereof. In the method, the polydopamine coating is combined with the nano-graphyne for the first time to construct a GDY@PDA composite system, and the core defects of the blocky graphyne, such as easy agglomeration, poor water solubility and insufficient biocompatibility, are solved. The graphyne-based material is applied to the near-infrared two-region photothermal regulation of neural cell calcium influx for the first time, the calcium ion channel is activated through the local thermal effect of the material, and precise, remote and reversible calcium influx regulation is realized; the limitation that the traditional biocompatibility modification is easy to fall off and difficult to functionalize is broken through, the polydopamine modification makes the material have both photothermal efficiency and biological safety, and the application of the graphyne in the treatment of neural diseases (such as neural cell injury repair) is expanded.

The invention relates to the technical field of nerve cell differentiation, and discloses a culture medium for promoting neural differentiation of SH-SY5Y cells. The culture medium disclosed by the invention is prepared from the following components: tazarotene (tazarotene) and a basic culture medium. The culture medium can promote SH-SY5Y cells to present neuron-like differentiation within 5 days, significantly improves the length of neurite and the expression level of neuron markers, and is low in cytotoxicity. The invention provides an efficient, safe and standardized new tool for neural disease in-vitro model construction, drug screening and mechanism research.

The application discloses a high-channel clinical microelectrode array intelligent brain function positioning system and method, and belongs to the fields of electronic information and clinical disease diagnosis and treatment technologies. The system comprises a microelectrode array implanted in the brain, a signal processing and transmission unit and a signal identification unit. The microelectrode array adopts a multi-channel design, can synchronously detect neural electrophysiological signals and transmitter chemical signals of different depths and directions, and has a resolution of a single cell level. The signal processing and transmission unit is responsible for signal acquisition, amplification and transmission, and applies electrical stimulation; the signal identification unit performs real-time processing on the signals through a convolutional neural network algorithm, quickly identifies target nuclei, and realizes accurate positioning. The application can realize real-time monitoring of neural cell discharges and transmitter releases at different depths and different directions, and can realize rapid and accurate target positioning with the aid of advanced intelligent algorithms, thereby providing a more reliable basis for DBS surgery.

A method for assessing differentiation potential of cells in a culture broth in the differentiation of pluripotent stem cells into neural cells of the midbrain floor plate region, comprising: measuring a concentration of NT-3 in a culture supernatant in a culture broth obtained by culturing the pluripotent stem cells in a medium containing an inducer of differentiation into the neural cells of the midbrain floor plate region; comparing the measured concentration of NT-3 with a reference concentration; and when the concentration of NT-3 is equal to or more than the reference concentration, assessing the cells in the culture broth as capable of differentiating into the neural cells of the midbrain floor plate region, wherein the culture supernatant is a culture supernatant collected from the culture broth at any time from 48 hours to 240 hours after the start of culture of the pluripotent stem cells.

A method of activating a piezoelectric neuroconduit guide scaffold including a plurality of aligned piezoelectric polymer nanofibers, the method including mechanically stimulating the piezoelectric neuroconduit guide scaffold with hydro-acoustic waves or shockwaves to remotely activate a piezoelectric effect of the nanofibrous scaffolds that induces a mechano-electrical stimulus on neural cells cultured on the scaffold, wherein the mechano-electrical stimulus promotes nerve fiber outgrowth from the neuronal cells. Some aspects relate to seeding individual components of neural tissues on the piezoelectric neuroconduit guide scaffold, wherein the hydro-acoustic stimulation induces neural tissue formation. In other aspects, the piezoelectric neuroconduit guide scaffold is implanted in a damaged neural tissue, wherein stimulating the piezoelectric neuroconduit guide scaffold by the application of shockwaves promotes nerve fiber outgrowth that bridges a nerve gap to induce nerve regeneration or reinnervation of the damaged neural tissue.

The invention relates to a method for efficiently producing a stomach-like organ with a self-organizing asymmetric pattern, and belongs to the technical field of organ culture. The invention provides a new application of the nerve cell precursor cell, the nerve cell precursor cell can promote posterior anterior intestine sphere differentiation to obtain a stomach organ with a self-organizing stomach fundus-antral pattern (free-antral pattern) characteristic, the structure and the cell lineage of the stomach organ are similar to those of an in-vivo stomach organ, and the stomach organ has better fidelity. The method provided by the invention is suitable for various human pluripotent stem cells, and can be used for efficiently producing asymmetric stomach organs.

The invention belongs to the technical field of biomedical materials, and discloses polydopamine modified nano graphdiyne as well as a preparation method and application thereof. According to the method, a polydopamine coating is combined with nano graphdiyne for the first time, a GDY and PDA composite system is constructed, and the core defects that blocky graphdiyne is prone to agglomeration, poor in water solubility and insufficient in biocompatibility are overcome. The graphdiynyl material is applied to near-infrared two-region photo-thermal regulation and control of nerve cell calcium internal flow for the first time, a calcium ion channel is activated through the local warming effect of the material, and accurate, remote and reversible calcium internal flow regulation and control are achieved; the limitation that traditional biocompatibility modification is easy to fall off and difficult to functionalize is broken through, the material has photo-thermal efficiency and biological safety through polydopamine modification, and the application of graphdiyne in nerve disease treatment (such as nerve cell damage repair) is expanded.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

The present invention relates to a neuroprotective drug for Parkinson's disease and its application, and relates to the field of biomedicine technology. + Treatment of SH-SY5Y neural cell line to establish MPP + In a cell model of PD induced by PD, N-[5-acetyl-1-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-1H-pyrrol-3-yl]acetamide was used for intervention. Cell viability, cytotoxicity and mitochondrial membrane potential were detected after intervention. It was found that N-[5-acetyl-1-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-1H-pyrrol-3-yl]acetamide could reduce MPP + Induced SH‑SY5Y cell damage and cytotoxicity, improved MPP in SH‑SY5Y cells + Caused by mitochondrial dysfunction.

The invention discloses an effect of TMEM159 in preparation of a medicine for treating cerebral ischemia reperfusion injury. According to the application disclosed by the invention, molecular biology experiments find that the expression of the TMEM159 in cerebral ischemia reperfusion brain tissues is reduced, and single cell sequencing data in a public database shows that the TMEM159 is mainly expressed in neuronal cells; an AAV9-mediated nerve cell specific TMEM159 overexpression adeno-associated virus vector is further constructed to verify the application of TMEM159 as a treatment target, and the result shows that the TMEM159 overexpression can reduce the cerebral infarction area caused by cerebral ischemia and reduce the cell apoptosis level; therefore, the invention provides a new therapeutic target and medicine for the cerebral ischemia disease, and the TMEM159 overexpression adeno-associated virus provided by the invention has the advantages of long-term expression, low toxicity, low immunogenicity, high tissue specificity and the like, and has good application prospects and transformation values.

The present invention relates to a method for producing neuronal cells from dedifferentiated adipocytes derived from a mammal, the method comprising a step for culturing dedifferentiated adipocytes derived from a mammal using a medium that contains a basic fibroblast growth factor (bFGF), retinoic acid, and a neuronal differentiation inducer, but does not substantially contain an epigenetic inhibitor.

A method of promoting compensatory plasticity of spared neural cells after a neural injury includes contacting the spared neural cells with an effective amount of a therapeutic agent comprising a therapeutic peptide, wherein the therapeutic peptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO:32.

The present invention relates to a method for culturing neural cells and to a neural organoid for use in medical or diagnostic treatment.

The present invention provides a method for inducing the differentiation of pluripotent stem cells into dopaminergic neural cells or a method for producing a cell group containing dopaminergic neural cells from pluripotent stem cells, each of the methods comprising: (1) bringing the pluripotent stem cells into contact with a TGFβ inhibitor, a BMP inhibitor, and / or a GSK3β inhibitor; and (2) expressing Ascl1 gene in the pluripotent stem cells.

Methods and systems including a first electrode substrate having one or more stimulation electrodes that are configured to apply electrical stimulation signals to a patient's first eye; a plurality of sensor electrodes configured to detect electrical activity from retinal or neural cells of the patient during delivery of an electrical-stimulation therapy, wherein the plurality of sensor electrodes includes a first sensor electrode and a second sensor electrode; a first return electrode configured to be placed in a location on the patient such that an electrical current is formed between at least one of the one or more stimulation electrodes and the first return electrode; and a stimulation controller configured to control the electrical current formed between the at least one of the one or more stimulation electrodes and the first return electrode such that the electrical current passes through a retina of the patient's first eye and delivers the electrical-stimulation therapy.

The object of this invention is to provide a method of producing a nerve bundle including efficiently extending axons of neural cells. As a solution to accomplish this end, neural cells are cultivated in the presence of feeder cells including at least one type of cells selected from vascular component cells and perivascular cells.

An object of the present invention is to provide a method of evaluating intercellular interactions in neuroinflammation using a co-culture containing human-derived neural cells capable of mimicking human brain functions. According to the present invention, there is provided a method of evaluating intercellular interactions in neuroinflammation, the method including a step of producing a co-culture containing at least two cells selected from the group consisting of human-derived astrocytes, human-derived neurons, human-derived microglia, and human-derived oligodendrocytes, a step of applying an inflammatory stimulation to a first cell contained in the co-culture, a step of detecting at least one selected from the group consisting of an inflammatory response marker in the cells contained in the co-culture, neural activity of the cells, and cell morphology, and a step of evaluating, over time, a change in at least one selected from the group consisting of the inflammatory response marker, the neural activity, and the cell morphology in the first cell and a second cell different from the first cell contained in the co-culture.

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

The present invention relates to a method for measuring, haemodialysis-associated brain ischemia, haemodialysis-associated brain hypoxia, and / or haemodialysis-associated neural cell death in a human subject based on the quantification of neuronal and / or glial cfDNA methylation profile. The invention further relates to a kit comprising a set of capture probe and its use.

The invention discloses a nerve cell differentiated from an immunoprivilege induced pluripotent stem cell and an application thereof. After main histocompatibility complex HLA-I and II type genes are inactivated in induced pluripotent stem cells, fusion protein XSG006 constructed by functional structural domains of CD47 and CD24 is over-expressed, the obtained induced pluripotent stem cells are differentiated to obtain separated low-immunogenicity dopaminergic neural precursor cells, and the low-immunogenicity dopaminergic neural precursor cells can be used for preparing the low-immunogenicity dopaminergic neural precursor cells on the basis of attack of escape T cells. And further, the NK cells and macrophages are escaped for killing. And attacks of an immune system can be effectively escaped in vivo. In a mouse Parkinson's disease model and a non-human primate (NHP) Parkinson's disease model, the strain can continuously survive in a host for a long time and generate activity, and the Parkinson's disease is fundamentally reversed. And an experimental basis and a theoretical basis are provided for establishing a PD treatment strategy and designing a novel stem cell treatment medicine.

The present application relates to the technical field of nano-preparation, in particular to an extracellular vesicle-liposome hybrid nanoparticle and a preparation method and application thereof. The extracellular vesicle-liposome hybrid nanoparticle provided by the present application significantly improves the ability of drugs to cross the blood-brain barrier and the target enrichment efficiency of ischemic lesions in the brain through active targeting modification; the specific response release of drugs is realized by using the high active oxygen microenvironment of the lesion, non-specific distribution of drugs is reduced, and the systemic toxic side effects are reduced; ultimately, a multi-target point synergistic treatment system capable of synchronously regulating neural cell apoptosis, glial cell inflammatory activation, brain microvascular endothelial cell ferroptosis and the structural integrity of the blood-brain barrier is constructed, the problem that the effect of traditional single target point intervention is limited is broken through from the root, and a more efficient, safe and precise new treatment strategy is provided for cerebral ischemia-reperfusion injury.

An antibody targeting an ATRN protein or an antigen-binding fragment thereof, and the use thereof, and belongs to the field of antibodies. The antibody or the antigen-binding fragment thereof comprises a heavy chain complementarity determining region HCDR, wherein the HCDR comprises at least one selected from amino acid sequences of SEQ ID NOs: 1-3 or an amino acid sequence having at least 80% homology thereto. The antibody or the antigen-binding fragment thereof is capable of binding to a human ATRN protein with high specificity and affinity, blocking the interaction thereof with receptors, inhibiting the signal transduction process, and restoring cell activity, thereby regulating obesity, melanin deposition, neural cell function and anti-tumor function of immune cells in organisms.